You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Article info

Article menu

Download PDFPDF

XML
Research Article
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors

Authors

  • Kohei Shitara Department of Gastrointestinal OncologyNational Cancer Center Hospital East Kashiwa Japan PubMed articlesGoogle scholar articles
  • Satoshi Ueha Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan Department of Molecular Preventive MedicineGraduate School of Medicine, The University of Tokyo Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Shigeyuki Shichino Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan Department of Molecular Preventive MedicineGraduate School of Medicine, The University of Tokyo Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Hiroyasu Aoki Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan Department of Molecular Preventive MedicineGraduate School of Medicine, The University of Tokyo Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Haru Ogiwara Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan Department of Molecular Preventive MedicineGraduate School of Medicine, The University of Tokyo Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Tetsuya Nakatsura Division of Cancer Immunetherapy, National Cancer Center, Exploratory Oncology Research and Clinical Trial Center (EPOC) Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Toshihiro Suzuki Division of Cancer Immunetherapy, National Cancer Center, Exploratory Oncology Research and Clinical Trial Center (EPOC) Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Manami Shimomura Division of Cancer Immunetherapy, National Cancer Center, Exploratory Oncology Research and Clinical Trial Center (EPOC) Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Toshiaki Yoshikawa Division of Cancer Immunetherapy, National Cancer Center, Exploratory Oncology Research and Clinical Trial Center (EPOC) Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Kayoko Shoda Division of Cancer Immunetherapy, National Cancer Center, Exploratory Oncology Research and Clinical Trial Center (EPOC) Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Shigehisa Kitano Department of Experimental TherapeuticsNational Cancer Center Hospital Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Makiko Yamashita Department of Experimental TherapeuticsNational Cancer Center Hospital Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Takayuki Nakayama Department of Experimental TherapeuticsNational Cancer Center Hospital Chuo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Akihiro Sato Clinical Research Support OfficeNational Cancer Center Hospital East Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Sakiko Kuroda Clinical Research Support OfficeNational Cancer Center Hospital East Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Masashi Wakabayashi Clinical Research Support OfficeNational Cancer Center Hospital East Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Shogo Nomura Clinical Research Support OfficeNational Cancer Center Hospital East Kashiwa Chiba Japan PubMed articlesGoogle scholar articles
  • Shoji Yokochi Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan IDAC Theranostics Inc. Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Satoru Ito Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan IDAC Theranostics Inc. Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Kouji Matsushima Division of Molecular Regulation of Inflammatory and Immune DiseasesResearch Institute for Biomedical Sciences, Tokyo University of Science 2669 Yamazaki 278-0022 Noda Chiba Japan Department of Molecular Preventive MedicineGraduate School of Medicine, The University of Tokyo Bunkyo-ku Tokyo Japan PubMed articlesGoogle scholar articles
  • Toshihiko Doi Department of Experimental TherapeuticsNational Cancer Center Hospital East 6-5-1 Kashiwanoha 277-8577 Kashiwa Chiba Japan PubMed articlesGoogle scholar articles

Citation

Shitara K, Ueha S, Shichino S, et al
First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2019;7:195. doi: 10.1186/s40425-019-0677-y
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.